Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) issued an announcement. Recently, Fujian Shengdi Pharmaceutical Co., Ltd., a subsidiary of the company, received a notice from the State Drug Administration to approve the addition of a Class 1 innovative drug independently developed by the company and China's first ultra-long-lasting original dual-target emetic injection with phosphorapitamparonosetron for injection.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) issued an announcement. Recently, Fujian Shengdi Pharmaceutical Co., Ltd., a subsidiary of the company, received a notice from the State Drug Administration to approve the addition of a Class 1 innovative drug independently developed by the company and China's first ultra-long-lasting original dual-target emetic injection with phosphorapitamparonosetron for injection.